Inflammatory cytokine biomarkers of asymptomatic sexually transmitted infections and vaginal dysbiosis: a multicentre validation study.


Journal

Sexually transmitted infections
ISSN: 1472-3263
Titre abrégé: Sex Transm Infect
Pays: England
ID NLM: 9805554

Informations de publication

Date de publication:
02 2019
Historique:
received: 18 12 2017
revised: 11 05 2018
accepted: 15 06 2018
pubmed: 19 7 2018
medline: 4 4 2019
entrez: 19 7 2018
Statut: ppublish

Résumé

Vaginal dysbiosis and STIs are important drivers of the HIV epidemic and reproductive complications. These conditions remain prevalent, partly because most cases are asymptomatic. We have shown that inflammatory cytokines interleukin (IL)-1α, IL-1β and interferon-γ-induced protein (IP)-10 are biomarkers for detecting asymptomatic STIs and vaginal dysbiosis (bacterial vaginosis (BV) or intermediate microbiota). This study aimed to validate the performance of these biomarkers in African women recruited regardless of symptoms. IL-1α, IL-1β and IP-10 were measured in menstrual cup secretions, endocervical, lateral vaginal wall and vulvovaginal swabs from 550 women from Pretoria, Soweto and Cape Town, South Africa and Bondo, Kenya using Luminex and ELISA. STIs were assessed by PCR, BV by Nugent scoring and vaginal microbiota by 16S rRNA sequencing. Across four study populations and four types of genital specimens, the performance of IL-1α, IL-1β and IP-10 for identification of women with STIs, BV or intermediate microbiota was consistent. Of the genital samples assessed, biomarkers measured in lateral vaginal wall swabs performed best, correctly classifying 76%(95% CI 70% to 81%) of women according to STI, BV or intermediate microbiota status (sensitivity 77%, specificity 71%) and were more accurate than clinical symptoms (sensitivity 41%, specificity 57%) (p=0.0003). Women incorrectly classified as STI/BV positive using the biomarkers had more abundant dysbiosis-associated bacteria, including An inexpensive, point-of-care screening test including IL-1α, IL-1β and IP-10 (and potentially pH) could be used in resource-limited settings to identify women with asymptomatic STIs and dysbiosis. These women could then be referred for aetiological testing, followed by specific treatment.

Identifiants

pubmed: 30018088
pii: sextrans-2017-053506
doi: 10.1136/sextrans-2017-053506
doi:

Substances chimiques

Biomarkers 0
CXCL10 protein, human 0
Chemokine CXCL10 0
Cytokines 0
IL1A protein, human 0
IL1B protein, human 0
Interleukin-1alpha 0
Interleukin-1beta 0
RNA, Ribosomal, 16S 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

5-12

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: JASP and LM, together with the University of Cape Town, have submitted a Patent application for IP-10 and IL-1α/β use for diagnosing an inflammatory condition in the female genital tract likely caused by an STI or BV.

Auteurs

Lindi Masson (L)

Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town, South Africa.
Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.

Shaun Barnabas (S)

Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town, South Africa.
Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa.

Jennifer Deese (J)

Contraceptive Technology and Innovation Department, Family Health International 360, Durham, North Carolina, USA.
Department of Epidemiology, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Katie Lennard (K)

Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town, South Africa.

Smritee Dabee (S)

Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town, South Africa.

Hoyam Gamieldien (H)

Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town, South Africa.

Shameem Z Jaumdally (SZ)

Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town, South Africa.

Anna-Lise Williamson (AL)

Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town, South Africa.

Francesca Little (F)

Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa.

Lut Van Damme (L)

The Bill & Melinda Gates Foundation, Seattle, Washington, USA.

Khatija Ahmed (K)

Setshaba Research Centre, Pretoria, South Africa.

Tania Crucitti (T)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

Saïd Abdellati (S)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

Linda-Gail Bekker (LG)

Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town, South Africa.
Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa.

Glenda Gray (G)

Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
South African Medical Research Council, Cape Town, South Africa.

Janan Dietrich (J)

Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.

Heather Jaspan (H)

Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town, South Africa.
Seattle Children's Research Institute, University of Washington, Seattle, Washington, USA.

Jo-Ann S Passmore (JS)

Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town, South Africa.
Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
National Health Laboratory Service, Johannesburg, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH